USA flag logo/image

An Official Website of the United States Government

Multiplexed Gene Assays by Microtiter Plate Microarrays

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65977
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
AI056008
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APATH, LLC
APATH, LLC 893 N. WARSON RD. SAINT LOUIS, MO 63141
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Multiplexed Gene Assays by Microtiter Plate Microarrays
Agency: HHS
Contract: 1R43AI056008-01
Award Amount: $111,600.00
 

Abstract:

DESCRIPTION (provided by applicant): The drug discovery industry is under increasing pressure to rapidly prioritize compound candidates based on their efficacy and specificity. Although traditional chip based gene expression microarrays can provide significant insights, sample format and throughput considerations preclude more widespread use. Microtiter plate based microarray (MPMA) systems can be directly integrated into the existing drug discovery process and would address the need for high sample throughput multiplexed gene expression assays. Apath LLC, an antiviral drug discovery company, and ProteoPlex, a microtiter plate based microarray company propose a collaboration to develop a multiplexed gene expression assay suitable for drug discovery applications such as toxicant identification. ProteoPlex has developed systems for spotting up to 144 oligonucleotide probes per microtiter well and Apath has well characterized viral replicon systems and cytotoxicity data that facilitate assay validation. We initially plan to optimize assay sensitivity and reproducibility through use of purified in vitro transcripts and modification of the probe deposition, hybridization, and cDNA target labeling conditions. We will next demonstrate that the MPMA can faithfully reproduce dose response effects by focusing on the well characterized interferon mediated inhibition of viral replicon RNAs. Finally, we will demonstrate the utility of the MPMA in identification of active and toxic compounds by performing blinded screens on panels of well-characterized compounds and comparing the results to those obtained in standard cytotoxicity assays.

Principal Investigator:

Paul D. Olivo
3148128144
OLIVO@APATH.COM

Business Contact:


3148128160
Small Business Information at Submission:

APATH, LLC
893 N. WARSON RD. ST. LOUIS, MO 63141

EIN/Tax ID: 431828778
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No